The Effects of RPL554 in Addition to Tiotropium in COPD Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Chronic Obstructive Pulmonary Disease Moderate

Interventions

DRUG

1.5 mg RPL554 plus tiotropium

DRUG

6 mg RPL554 plus tiotropium

DRUG

Placebo plus tiotropium

All Listed Sponsors

lead

Verona Pharma plc

INDUSTRY

NCT03028142 - The Effects of RPL554 in Addition to Tiotropium in COPD Patients | Biotech Hunter | Biotech Hunter